Monday, February 6, 2023
Google search engine
HomeMarketResultsDipal Doshi Sells 2,410 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Dipal Doshi Sells 2,410 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock


Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating) CEO Dipal Doshi offered 2,410 shares of the agency’s inventory in a transaction dated Monday, January ninth. The shares have been offered at a median value of $15.02, for a complete transaction of $36,198.20. Following the completion of the sale, the chief govt officer now owns 165,835 shares of the corporate’s inventory, valued at roughly $2,490,841.70. The transaction was disclosed in a doc filed with the SEC, which is offered at this link.

Dipal Doshi additionally not too long ago made the next commerce(s):

  • On Thursday, December twenty ninth, Dipal Doshi offered 400 shares of Entrada Therapeutics inventory. The shares have been offered at a median value of $15.01, for a complete transaction of $6,004.00.
  • On Tuesday, December twenty seventh, Dipal Doshi offered 9,669 shares of Entrada Therapeutics inventory. The inventory was offered at a median value of $15.02, for a complete transaction of $145,228.38.
  • On Monday, November twenty eighth, Dipal Doshi offered 2,000 shares of Entrada Therapeutics inventory. The inventory was offered at a median value of $13.91, for a complete transaction of $27,820.00.
  • On Thursday, October twenty seventh, Dipal Doshi offered 2,000 shares of Entrada Therapeutics inventory. The inventory was offered at a median value of $21.66, for a complete transaction of $43,320.00.
  • On Monday, October twenty fourth, Dipal Doshi offered 2,342 shares of Entrada Therapeutics inventory. The inventory was offered at a median value of $19.30, for a complete transaction of $45,200.60.
  • On Thursday, October twentieth, Dipal Doshi offered 811 shares of Entrada Therapeutics inventory. The inventory was offered at a median value of $18.01, for a complete transaction of $14,606.11.

Entrada Therapeutics Worth Efficiency

TRDA traded down $0.34 throughout buying and selling on Tuesday, reaching $14.89. The corporate had a buying and selling quantity of 99,167 shares, in comparison with its common quantity of 62,084. Entrada Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month excessive of $24.38. The enterprise’s fifty day transferring common value is $16.91 and its 200 day transferring common value is $14.93. The corporate has a market cap of $467.64 million, a P/E ratio of -4.77 and a beta of -0.79.

Entrada Therapeutics (NASDAQ:TRDAGet Rating) final introduced its quarterly earnings outcomes on Monday, November seventh. The corporate reported ($0.80) earnings per share for the quarter. As a bunch, sell-side analysts predict that Entrada Therapeutics, Inc. will put up -3.08 EPS for the present fiscal 12 months.

Wall Road Analyst Weigh In

TRDA has been the topic of a number of analyst stories. The Goldman Sachs Group lifted their value goal on shares of Entrada Therapeutics from $13.00 to $18.00 and gave the inventory a “impartial” ranking in a analysis report on Tuesday, November eighth. William Blair reissued an “outperform” ranking on shares of Entrada Therapeutics in a analysis word on Friday, October 14th.

Institutional Inflows and Outflows

Various institutional traders have not too long ago purchased and offered shares of TRDA. Worth T Rowe Associates Inc. MD lifted its stake in Entrada Therapeutics by 21.9% within the third quarter. Worth T Rowe Associates Inc. MD now owns 2,972,050 shares of the corporate’s inventory valued at $46,840,000 after shopping for an extra 534,552 shares within the final quarter. Nan Fung Group Holdings Ltd purchased a brand new stake in shares of Entrada Therapeutics within the first quarter price $1,630,000. Laurion Capital Administration LP purchased a brand new stake in shares of Entrada Therapeutics within the second quarter price $1,572,000. Vanguard Group Inc. lifted its place in shares of Entrada Therapeutics by 14.1% within the third quarter. Vanguard Group Inc. now owns 870,147 shares of the corporate’s inventory price $13,714,000 after buying an extra 107,783 shares within the final quarter. Lastly, BlackRock Inc. lifted its place in shares of Entrada Therapeutics by 127.1% within the third quarter. BlackRock Inc. now owns 147,593 shares of the corporate’s inventory price $2,326,000 after buying an extra 82,594 shares within the final quarter. Institutional traders personal 78.08% of the corporate’s inventory.

Entrada Therapeutics Firm Profile

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology firm, develops endosomal escape car (EEV) therapeutics for the therapy of a number of neuromuscular illnesses. Its endosomal escape car platform develops a portfolio of oligonucleotide, antibody, and enzyme-based applications. The corporate’s lead product candidate is ENTR-601-44, which is in preclinical path for the therapy of Duchenne muscular dystrophy and myotonic dystrophy kind 1.

Additional Studying

Insider Buying and Selling by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Entrada Therapeutics, you will wish to hear this.

MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their shoppers every day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Entrada Therapeutics wasn’t on the checklist.

Whereas Entrada Therapeutics at the moment has a “Average Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The Five Stocks Here



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments